Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/20/22
End: 11/20/25
Due: 11/20/26
Phase: N/A
Priority: Normal
Start: 04/09/19
End: 06/03/24
Due: 06/03/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) | NCT05276076 | ViGenCell Inc. | user2@example.com | None | 2022-11-20 | 2025-11-20 | 2026-11-20 | - | - | 2025-07-14 |
| VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | NCT03671850 | ViGenCell Inc. | user2@example.com | None | 2019-04-09 | 2024-06-03 | 2025-06-03 | - | - | 2025-07-14 |